quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:46:35·139d
ANALYSTRating
X4 Pharmaceuticals Inc. logo

Stifel resumed coverage on X4 Pharmaceuticals with a new price target

XFOR· X4 Pharmaceuticals Inc.
Health Care
Original source

Companies

  • XFOR
    X4 Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Mar 9UpdateGuggenheim$12.00
  • Dec 5UpdateStifel$10.00
  • Dec 12UpdateB. Riley Securities$1.00
  • Aug 30UpdateB. Riley Securities$3.00
  • Dec 22UpdateCantor Fitzgerald$3.00
  • Dec 12UpdatePiper Sandler$3.00

Related

  • PR22d
    X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • SEC34d
    SEC Form DEFA14A filed by X4 Pharmaceuticals Inc.
  • SEC34d
    SEC Form DEF 14A filed by X4 Pharmaceuticals Inc.
  • PR37d
    X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
  • SEC37d
    SEC Form 10-K filed by X4 Pharmaceuticals Inc.
  • ANALYST45d
    Guggenheim initiated coverage on X4 Pharmaceuticals with a new price target
  • SEC48d
    Amendment: SEC Form SCHEDULE 13G/A filed by X4 Pharmaceuticals Inc.
  • PR50d
    X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022